$JAZZ News
Last published 1w ago
- 1w agoJAZZJazz Pharmaceuticals plc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoJAZZZiihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026PR NewswireNearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 monthsMature HERIZON-GEA-01 results show Ziihera plus chemotherapy
- 1mo agoJAZZJazz Pharmaceuticals Completes Acquisition of Actio BiosciencesPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of privately-held...
- 2mo agoJAZZJazz Pharmaceuticals to Participate in Upcoming Investor ConferencesPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor...
- 2mo agoJAZZZiihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEAPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial...
- 2mo agoJAZZJazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875%...
- 2mo agoJAZZJazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the...
- 2mo agoJAZZU.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera®...
- 3mo agoJAZZJazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy PortfolioPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive...
- 3mo agoJAZZJazz Pharmaceuticals Announces Second Quarter 2026 Financial ResultsPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026. ...
- 3mo agoJAZZJazz Pharmaceuticals Announces Second Quarter 2026 Financial ResultsPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026. ...
- 3mo agoJAZZJazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026PR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the ...
- 4mo agoABCLJAZZJazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific AntibodiesBusiness WireThe collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop Jazz has the
- 4mo agoJAZZABCLJazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific AntibodiesPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license...
- 4mo agoJAZZJazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic HypersomniaPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the...
- 5mo agoJAZZJazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung CancerPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca®...
- 5mo agoJAZZJazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic HypersomniaPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP...
- 5mo agoJAZZPhase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEAPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial...
- 6mo agoJAZZJazz Pharmaceuticals to Participate in Upcoming Investor ConferencesPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor...
- 6mo agoJAZZJazz Pharmaceuticals Announces First Quarter 2026 Financial ResultsPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2026 (1Q26). "Our first-quarter results reflect...
- 6mo agoJAZZJazz Pharmaceuticals Announces First Quarter 2026 Financial ResultsPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2026 (1Q26). "Our first-quarter results reflect...
- 6mo agoJAZZJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEAPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the ...
- 6mo agoJAZZJazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026PR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the...
- 6mo agoJAZZJazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)PR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present three rapid oral and seven poster...
- 7mo agoJAZZJazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual MeetingPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present six abstracts, including one oral presentation, at the 2026...
- 7mo agoJAZZJazz Pharmaceuticals to Participate in Needham Virtual Healthcare ConferencePR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25th Annual Needham Healthcare Conference. Company...
- 7mo agoJAZZAmerican Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health EducationPR NewswireThe American Nutrition Association (ANA) today announced its initiative with Jazz Pharmaceuticals to provide evidence-based nutritional education to...
- 7mo agoJAZZJazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026PR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company and its partners will present one oral and six poster presentations at the...
- 8mo agoCMPXMRKSGENPFE+8Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightPR NewswireThe biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing...
- 8mo agoJAZZJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial GuidancePR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial...
- 8mo agoJAZZJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial GuidancePR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial...
- 8mo agoJAZZJazz Pharmaceuticals to Participate in Upcoming Investor ConferencesPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences: TD Cowen 46th Annual ...
- 9mo agoJAZZJazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026PR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24,...
- 10mo agoJAZZBoehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancerGlobeNewswirePhase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical
- 10mo agoJAZZJazz Pharmaceuticals Appoints Thomas Riga as Chief Business OfficerPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga ...
- 10mo agoJAZZZiihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival BenefitPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating...
- 10mo agoJAZZJazz Pharmaceuticals to Participate in Upcoming Investor EventsPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab...
- 10mo agoJAZZJazz Pharmaceuticals to Participate in Upcoming Investor EventsPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab...
- 11mo agoJAZZJazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual MeetingPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts, including four that are late-breaking, will be presented on Epidiolex®...
- 11mo agoJAZZJazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers SymposiumPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced two abstracts featuring key data for Ziihera® (zanidatamab-hrii) have been accepted for...
- 11mo agoJAZZJazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare ConferencePR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company...
- 11mo agoJAZZPositive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal AdenocarcinomaPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera®...
- 1y agoJAZZJazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025PR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO)...
- 1y agoJAZZJazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial GuidancePR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2025 and updated financial guidance for 2025....
- 1y agoJAZZJazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial GuidancePR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2025 and updated financial guidance for 2025....
- 1y agoJAZZJazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of DirectorsPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective...
- 1y agoJAZZJazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025PR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025,...
- 1y agoJAZZFDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for Zepzelca®...
- 1y agoJAZZJazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych CongressesPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav® (calcium, magnesium, ...
- 1y agoJAZZModeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse GliomaPR NewswireJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network®...